

EDITORIAL COMMENT

Claudication

Pay for Structured Exercise or Go Take a Hike*

Neal N. Sawlani, MD, MPH, Scott Kinlay, MBBS, PhD



Intermittent claudication is the most common symptomatic manifestation of lower extremity peripheral artery disease. It is a withering symptom that impairs walking function and decreases quality of life. Although many successful therapies lower atherosclerosis risk factors to prevent the high risk for cardiovascular events, there are few medical therapies to improve walking impairment and physical independence in patients with claudication.

Cilostazol is the only medication that improves the claudication distance (the distance before onset of claudication) and maximal walking distance (the distance before stopping because of symptoms), common measures of walking impairment. However, the effect is modest and variable, with meta-analyses estimating a 25% increase in claudication distance (1). In contrast, several randomized trials have shown that supervised exercise training increases claudication distance by 30% to 100% (2-4).

Supervised exercise training is rarely used in clinical practice in the United States, for 2 reasons. First, it is not covered by medical insurers, and second, it is sometimes difficult for patients to attend 3

supervised classes a week for several months. As a result, those of us who treat claudication can only advise patients to pay for supervised exercise out of their own pocket or keep walking, a prescription that is sometimes misinterpreted as “go take a hike [out of my office].” In contrast, revascularization, particularly by endovascular techniques, provides a relatively immediate “fix” for both the patient (improved walking) and the institution and provider (handsome insurance reimbursement).

SEE PAGE 712


In this issue of *JACC: Cardiovascular Interventions*, Pandey et al. (5) report on a meta-analysis in patients with peripheral artery disease designed to compare the benefit of revascularization, primarily by endovascular techniques, over the well-proven effects of supervised exercise training. Their analysis is divided into 2 comparisons: first, supervised exercise training alone versus revascularization alone, and second, supervised exercise training after revascularization versus supervised exercise training alone.

The key findings of the first comparison are that compared with supervised exercise alone, revascularization in 5 comparison groups improves the ankle-brachial index but does not improve walking impairment, repeat revascularization, or amputation. One of the studies in this comparison was a meta-analysis of studies that did not directly compare revascularization with supervised exercise training (6), but ignoring that study does not affect the overall conclusion from the forest plots that supervised exercise is equivalent to the widely reimbursed therapy of revascularization alone.

In the second analysis, the combination of supervised exercise after revascularization improved ankle-brachial index and maximal walking distance,

*Editorials published in *JACC: Cardiovascular Interventions* reflect the views of the authors and do not necessarily represent the views of *JACC: Cardiovascular Interventions* or the American College of Cardiology.

From the Veterans Affairs Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. This work was supported by VA Clinical Science Research and Development Awards 1/21CX000793 and 1/01CX001549 and by the Assistant Secretary of Defense for Health Affairs, through the Gulf War Illness Research Program under award W81XWH-15-1-0216. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the U.S. Department of Defense. Dr. Kinlay has received research support from Medtronic and The Medicines Company. Dr. Sawlani has reported that he has no relationships relevant to the contents of this paper to disclose.



with less repeat revascularization or amputation but no difference in the claudication distance (distance to onset of claudication) compared with supervised exercise alone (Figure 1). To be fair, there were only 2 minor amputations in the 454 subjects in the second comparison, so this effect largely reflects crossover to revascularization by subjects initially treated by supervised exercise training alone, at a respectable 37 patients (16%).

Overall, the study is a stunning reaffirmation of supervised exercise training, both compared with the well-reimbursed therapy of revascularization alone and, by implication, as an important adjunct to endovascular revascularization when this is deemed

necessary. The investigators should be congratulated for adding this revascularization perspective and supporting the conclusions of the recent intersociety guidelines for the management of peripheral artery disease (7,8). For patients who find it difficult to attend supervised exercise programs, structured home-based exercise programs may offer a solution to initial therapy or adjunctive therapy with revascularization. Structured home-based exercise programs start with a supervised training visit and an exercise prescription and other behavioral interventions. A provider reinforces this program through follow-up by telephone or other means to progressively increase exercise. Several randomized trials show that these programs improve walking impairment and may have similar effects to supervised exercise (9-12).

This report is very timely, as currently, representatives of several cardiovascular societies are lobbying the Centers for Medicare and Medicaid Services to reimburse supervised exercise training for patients with claudication. These include the American College of Cardiology, the American Heart Association, the Society for Vascular Medicine, the Society for Vascular Surgery, and others. We who treat patients with claudication have long recognized that the lack of insurance coverage for supervised exercise programs is a denial of the scientific evidence. Maybe the advice we should give insurers about supervised exercise therapy is the only message we currently appear to give our patients, namely, pay for structured exercise programs, or “go take a hike.”

ADDRESS FOR CORRESPONDENCE: Dr. Scott Kinlay, VA Boston Healthcare System, Cardiovascular Division, 1400 VFW Parkway, West Roxbury, Massachusetts 02132. E-mail: scott.kinlay@va.gov.

REFERENCES

1. Stevens JW, Simpson E, Harnan S, et al. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. *Br J Surg* 2012;99:1630-8.
2. Fakhry F, Spronk S, van der Laan L, et al. Endovascular revascularization and supervised exercise for peripheral arterial disease and intermittent claudication: a randomized clinical trial. *JAMA* 2015;314:1936-44.
3. Murphy TP, Cutlip DE, Regensteiner JG, et al., for the CLEVER Study Investigators. Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral arterial disease: six-month outcomes from the claudication: Exercise Versus Endoluminal Revascularization (CLEVER) study. *Circulation* 2012;125:130-9.
4. Fakhry F, van de Luijngaarden KM, Bax L, et al. Supervised walking therapy in patients with intermittent claudication. *J Vasc Med Biol* 2012;24:1132-42.
5. Pandey A, Banerjee S, Ngo C, et al. Comparative efficacy of endovascular revascularization versus supervised exercise training in patients with intermittent claudication: meta-analysis of randomized controlled trials. *J Am Coll Cardiol Intv* 2017;10:712-24.
6. Spronk S, Bosch JL, Veen HF, den Hoed PT, Hunink MG. Intermittent claudication: functional capacity and quality of life after exercise training or percutaneous transluminal angioplasty—systematic review. *Radiology* 2005;235:833-42.
7. TASC Steering Committee, Jaff MR, White CJ, Hiatt WR, et al. An update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: a supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *Vasc Med* 2015;20:465-78.
8. Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC guideline on the

management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol* 2017;69:1465-508.

9. McDermott MM, Guralnik JM, Criqui MH, et al. Home-based walking exercise in peripheral artery disease: 12-month follow-up of the GOALS randomized trial. *J Am Heart Assoc* 2014;3:e000711.

10. Nordanstig J, Taft C, Hensater M, Perlander A, Osterberg K, Jivegard L. Improved quality of life after 1 year with an invasive versus a noninvasive treatment strategy in claudicants: one-year results of the Invasive Revascularization or Not in Intermittent Claudication (IRONIC) trial. *Circulation* 2014;130:939-47.

11. Gardner AW, Parker DE, Montgomery PS, Scott KJ, Blevins SM. Efficacy of quantified home-based exercise and supervised exercise in patients with intermittent claudication: clinical perspective. *Circulation* 2011;123:491-8.

12. Gardner AW, Parker DE, Montgomery PS, Blevins SM. Step-monitored home exercise improves ambulation, vascular function, and inflammation in symptomatic patients with peripheral artery disease: a randomized controlled trial. *J Am Heart Assoc* 2014;3:e001107.

KEY WORDS claudication, reimbursement, revascularization, supervised exercise